By Maxx Chatsko The drug developer’s financing deal with Blackstone has several strings attached. The biotech sector has been whacked during the stock market correction, but companies with approved drug products have generally fared much better than early-stage peers. That doesn’t provide complete protection though. PTC Therapeutics (PTCT) – Get PTC Therapeutics Inc. Report saw shares drop by 13% after announcing an up to $1 billion financing deal with the life sciences arm of Blackstone (BX) – Get Blackstone Inc. Report. Investors were so distraught with the terms of the financing that they o…